Effective combinatorial immunotherapy for castration-resistant prostate cancer: new future chance?

Prostate cancer (pCa) is the second most common non-cutaneous malignant neoplasm in men worldwide, with an estimated incidence of 1.1 million new cases per year. Furthermore, it is the fifth leading cause of cancer-related death, representing 6.6% of total male mortality (1).